• Home
  • Latest
  • Fortune 500
  • Finance
  • Tech
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia
NewslettersBrainstorm Health

A Promising Pair of Ebola Drugs Raises Hopes in Africa: Brainstorm Health

By
Sy Mukherjee
Sy Mukherjee
Down Arrow Button Icon
By
Sy Mukherjee
Sy Mukherjee
Down Arrow Button Icon
August 12, 2019, 7:26 PM ET

Happy Monday, readers! I hope you had a wonderful weekend.

Let’s start off the week with a bit of positive news. A pair of experimental Ebola treatments have proven successful enough that they’ll be administered to all patients in the Congo, the National Institutes of Health said on Monday.

“Very encouraged that 2 arms of study in the DRC testing experimental treatments for #Ebola show that REGN-EB3 or mAb114 substantially benefited patients. All future patients will now receive either, in what will be an extension phase of the study,” wrote NIH director Francis Collins in a tweet.

Let’s break that down into simpler terms. The two treatments in question (REGN-EB3 and mAb114) are being developed, respectively, by the pharmaceutical giant Regeneron and the startup Ridgeback Biotherapeutics (although the latter was licensed mAb114, a monoclonal antibody, from the NIH itself).

Here’s the thing—these two Ebola cure wannabes have proven effective enough (and amid a devastating, difficult-to-contain outbreak in the Congo)—that global health officials believe local residents will actually be willing to take them. It’s a matter of trust fueled by (admittedly preliminary) efficacy.

Read on for the day’s news.

Sy Mukherjee, @the_sy_guy, sayak.mukherjee@fortune.com

INDICATIONS

Congress has noticed Novartis' data issues for its gene therapy. Drug giant Novartis continues to face the fallout from its data manipulation scandal for a $2.1 million gene therapy treatment called Zolgensma, Reuters reports. Sen. Chuck Grassley, chairman of the U.S. Senate Finance Committee, is seeking more information from the company regarding its internal investigations into alleged data manipulations (allegations which led the FDA to threaten potential criminal charges). Novartis CEO Vas Narasimhan said last week that the company had "tried to do the right things" with regards to the data issues, and that the employees involved in the matter were being removed. (Reuters)

THE BIG PICTURE

An American abroad is being accused of running an unlicensed medical facility. A U.S. citizen is being accused of operating a non-profit in Uganda meant to treat malnourished children that, according to the allegations, actually led to the deaths of hundreds of children. Renee Bach, a missionary, strongly denied those allegations to NBC News—while also admitting that more than 100 children died at the facility she operated. (NBC News)

REQUIRED READING

What the IRS Wants You to Know About Tax Scams, by The Associated Press

Tiny Luxembourg Is Having a Big Brexit Moment, by Josie Cox

Um, Where's the Recession? by Polina Marinova

Rite Aid Names New CEO, Brings Number of Women CEOs on Fortune 500 to Record High, by Bloomberg

Find past coverage. Sign up for other Fortune newsletters.

About the Author
By Sy Mukherjee
See full bioRight Arrow Button Icon

Latest in Newsletters

Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025

Most Popular

Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Rankings
  • 100 Best Companies
  • Fortune 500
  • Global 500
  • Fortune 500 Europe
  • Most Powerful Women
  • Future 50
  • World’s Most Admired Companies
  • See All Rankings
Sections
  • Finance
  • Leadership
  • Success
  • Tech
  • Asia
  • Europe
  • Environment
  • Fortune Crypto
  • Health
  • Retail
  • Lifestyle
  • Politics
  • Newsletters
  • Magazine
  • Features
  • Commentary
  • Mpw
  • CEO Initiative
  • Conferences
  • Personal Finance
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Fortune Brand Studio
  • Fortune Analytics
  • Fortune Conferences
  • Business Development
About Us
  • About Us
  • Editorial Calendar
  • Press Center
  • Work At Fortune
  • Diversity And Inclusion
  • Terms And Conditions
  • Site Map
  • Facebook icon
  • Twitter icon
  • LinkedIn icon
  • Instagram icon
  • Pinterest icon

Most Popular

placeholder alt text
North America
'I meant what I said in Davos': Carney says he really is planning a Canada split with the U.S. along with 12 new trade deals
By Rob Gillies and The Associated PressJanuary 28, 2026
1 day ago
placeholder alt text
C-Suite
Fortune 500 CEOs are no longer giving employees an A for effort. Now they want proof of impact
By Claire ZillmanJanuary 28, 2026
2 days ago
placeholder alt text
Success
Every U.S. Olympian is going home with $200,000, whether they medal or not, thanks to a billionaire's $100 million gift
By Jacqueline MunisJanuary 28, 2026
1 day ago
placeholder alt text
Politics
The American taxpayer spent nearly half a billion dollars deploying federal troops to U.S. cities in 2025, CBO finds
By Nick LichtenbergJanuary 28, 2026
1 day ago
placeholder alt text
Real Estate
Ryan Serhant thinks the American Dream was just a 'slogan created by banks,' but it was really about FDR, the Great Depression, and an economic crisis
By Sydney Lake and Nick LichtenbergJanuary 26, 2026
3 days ago
placeholder alt text
C-Suite
Jeff Bezos capped his Amazon salary at $80,000: ‘How could I possibly need more incentive?’
By Sydney LakeJanuary 28, 2026
1 day ago

© 2026 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
FORTUNE is a trademark of Fortune Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.


Latest in Newsletters

NewslettersEye on AI
AI has made hacking cheap. That changes everything for business
By Sharon GoldmanJanuary 29, 2026
4 hours ago
barra
NewslettersMPW Daily
GM’s earnings rally wasn’t just about quarterly results. It was about trust in Mary Barra
By Emma HinchliffeJanuary 29, 2026
5 hours ago
The company logo is displayed in front of the Archer Daniels Midland (ADM) facility in Decatur, Illinois.
NewslettersCFO Daily
ADM settles accounting scandal—can AI help prevent the next one?
By Sheryl EstradaJanuary 29, 2026
9 hours ago
NewslettersTerm Sheet
Inside the race to build data centers
By Allie GarfinkleJanuary 29, 2026
11 hours ago
NewslettersCEO Daily
A once-unthinkable C-suite appointment solidifies Walmart’s new identity as a tech company
By Phil WahbaJanuary 29, 2026
11 hours ago
NewslettersFortune Tech
Meta gets the love, Microsoft gets smacked
By Alexei OreskovicJanuary 29, 2026
11 hours ago